2022

NuGen Medical Devices Inc. (TSXV:NGMD)(OTCQB:NGMDF) (“NuGen” or the “Company”) announces that it has closed the first tranche of a non-brokered private placement through the issuance of 2,500,000 units (“Units”) at a price of $0.05 per Unit for gross proceeds of $125,000 (the “Offering”). Each Unit is comprised of one common share (“Common Share”) of the Company and one Common Share purchase warrant (“Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share for a period of sixty (60) months from the closing of the Offering at a price of $0.05 per Common Share. The proceeds of the offering will be used for general working capital purposes.

The Board of directors of NuGen Medical Devices Inc. (TSXV:NGMD)(OTCQB:NGMDF) (“NuGen” or the “Company”), a leader in needle-free drug delivery, announces the departure of Mr. Michael Wright, President and Chief Executive Officer, effective immediately. Mr. Wright remains a director and a shareholder of the Company and will assist with the management transition. The Company wishes Mr. Wright good luck with his future endeavors.

The Agreement, signed October 17, 2022, represents a minimum of ~CA$23M1 over the 5-year term and includes minimum commitments of 34,000 InsuJet™ devices plus additional accessories and is in line with the Company’s 70% gross margin target.

SOL-MILLENNIUM Medical Group (“Sol-Millennium” or “Sol-M”), a global healthcare company dedicated to the design, manufacturing, and distribution of high-quality medical devices and personal protective equipment for patients and clinicians around the world, has registered as an exhibitor at the 2022 Diabetes Canada/Canadian Society of Endocrinology and Metabolism (CSEM) Professional Conference, where it will launch the InsuJet™ product for Canada.

NuGen M.D. Receives Approval for its Netherlands Site to Manufacture Needle-Free Devices Under ISO 13485 QMS Certificate TORONTO, ON /

“Erik brings a creative approach to commercialization, patient engagement, and corporate partnerships,” said NuGen CEO Michael Wright. “We look forward to working with him and our growing advisory team as NuGen continues to develop our innovative medical delivery products.”

The patent would protect the refill design mechanism for NuGen’s needle-free injection device which allows for the insertion of the medicine vial directly into the device.

The Company received approval from the TSXV to extend the expiry term of the Warrants for an additional 12 months from September 30, 2022 to September 30, 2023, and to amend the exercise price of the Warrants from $0.70 per Warrant to $0.40 per Warrant.

“Greg brings a wealth of experience in needle-free and pharmaceutical technology to the table, making him an ideal fit for our Company as we continue to develop next-generation needle-free injection devices,” said Michael Wright, CEO of NuGen.

NuGen has made an application to the TSX Venture Exchange (the “TSXV”) to extend the expiry date and reduce the exercise price of an aggregate of 7,500,000 outstanding common share purchase warrants of the Company.

“This is an important milestone for Nugen,” said Michael Wright, CEO of NuGen. “Building on our recent OTCQB listing, DTC eligibility means that our stock will be even more accessible to trade for a broader range of U.S. investors.”

NuGen Medical Devices is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement through the issuance of 2,285,763 units at a price of $0.10 per Unit for gross proceeds of $228,576.30.

NuGen Medical Devices announces that in connection with the private placement originally announced in the Company’s press release of July 22, 2022, the Company has applied to the TSX Venture Exchange for an extension of a further 30 days price protection in order to complete further subscriptions.

NuGen M.D. is pleased to announce that, effective July 27, 2022, its common shares will commence trading on the OTCQB under the symbol NGMDF.

NuGen M.D. is pleased to announce that its needle-free injection system and accessories, also known as InsuJet™, has been approved by Health Canada specifically for the needle-free delivery of insulin.

NuGen M.D. is pleased to announce a five-year exclusive sales and distribution agreement with Sol-Millennium, a global healthcare company.

NuGen M.D. announces that it will be launching a needle-free injection device specifically designed for domesticated household pets.

NuGen M.D. is pleased to announce that all matters submitted to shareholders for approval as set out in detail in the Company’s management information circular dated May 17, 2022 were approved at the annual and special meeting of the shareholders of the Company held on June 17, 2022.

NuGen M.D., in collaboration with Unifire, Inc., submitted on June 14th, 2022, an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (“EUA”) of NuGen reusable needle-free jet injector (NFJI) systems.

NuGen Medical Devices Inc. (TSXV: NGMD) (“NuGen” or the “Company”), a leader in needle-free drug delivery, is pleased to announce the launch of a new online brand store for its InsuJetTM needle-free injection device.

NuGen selected Draganfly Inc. and Coldchain Delivery Systems, Inc. to provide drones and services for the delivery of InsuJet™, insulin, and other crucial medical supplies to Ukraine.

Kin Communications has joined forces with NuGen Medical Devices to raise funds in order to purchase insulin to be administered and delivered with NuGen M.D’s needle-free injection device also known as InsuJet™, to Ukrainian diabetics urgently in need of daily insulin injections to stay alive.

NuGen Medical Devices Inc. and Unifire, Inc. are pleased to announce they have entered into a Master Distribution and Marketing Agreement dated March 14 2022, whereas Unifire has been granted exclusive rights to sell NuGen M.D.’s needle-free injection device into various US Government agencies.

NuGen Medical Devices Inc. and Unifire, Inc. are pleased to announce they have entered into a Master Distribution and Marketing Agreement dated March 14 2022, whereas Unifire has been granted exclusive rights to sell NuGen M.D.’s needle-free injection device into various US Government agencies.

NuGen Medical Devices is pleased to announce that it has signed a 5-year distribution agreement (the “Agreement”) with Harrington Consultants Limited and its joint venture partner Al Mufid Pharmaceuticals (the “Kuwait Joint Venture” or the “Distributor”).

President Biden used insulin as an example of how he plans to cut the cost of prescription drugs. He talked about Joshua Davis, a 13-year-old boy with Type 1 diabetes and an advocate for lower prescription drug costs, who was a special guest of First Lady Jill Biden at the State of the Union Address.

TORONTO, Ontario – February 1, 2022 – NuGen Medical Devices Inc. (TSXV: NGMD) (“NuGen M.D.” or the “Company”), a leader

TORONTO, Ontario – January 18, 2022 – NuGen Medical Devices Inc. (TSXV: NGMD) (“NuGen M.D.” or the “Company”) is pleased

TORONTO, Ontario – January 12, 2022 – NuGen Medical Devices Inc. (TSXV: NGMD) (“NuGen” or the “Company“) is pleased to provide an overview